In Canada’s 2023 health survey, 10.8% of South Asian adults reported having diabetes, compared with 8.0% of the non-racialized population. The South Asian diabetes figure is a finding about a population in a particular year. It cannot tell an Indian-Canadian parent whether they have diabetes, or calculate a child’s chance of developing it.
The difference is a reason to take screening and access to care seriously, rather than a diagnosis attached to ancestry. For a family reading the figures on 14 October 2026, three checks matter: who was counted, what was measured and whether the number answers a personal health question. A change in any of those can change the meaning of a percentage.
The figures come from Statistics Canada’s Health of Canadians report and its 2023 Canadian Community Health Survey data. They are dated evidence, not a newly measured October 2026 prevalence rate. Clinical guidance and more recent research can help families decide what to ask, while leaving diagnosis to the appropriate assessment.
What do the South Asian diabetes figures actually measure?
They measure the share of the relevant survey population reporting diabetes in 2023. Statistics Canada’s table covers adults aged 18 and older, excludes territorial data from the annual estimates and compares the reported prevalence across racialized groups.
| Population in the 2023 table | Reported diabetes prevalence | What the number describes |
|---|---|---|
| South Asian adults | 10.8% | The survey estimate for this broad group |
| Non-racialized adults | 8.0% | The comparator group used in the report |
Statistics Canada identifies the difference as statistically significant. The table’s non-racialized category excludes Indigenous respondents. It is therefore not interchangeable with a figure for every Canadian outside the South Asian category, or with a rate for all people described as white in another study.
The report’s diabetes discussion includes type 1, type 2 and gestational diabetes. It is not a type 2-only estimate. A headline about future type 2 risk, a clinical study of undiagnosed diabetes and this survey table would be answering different questions even if each used a percentage.
What is prevalence?
Prevalence is the proportion of a defined population living with a condition during the period being measured. Incidence concerns new cases over a period. Neither measure, by itself, gives an individual a diagnosis or a personalised prediction.
Does South Asian mean Indian-Canadian in this dataset?
No. South Asian is a broader population category, not a synonym for Indian-Canadian. The category contains people with different national, regional, migration and family backgrounds. A group estimate cannot be relabelled as the rate among Indian citizens, people born in India or every family of Indian ancestry.
The same caution applies within a family. Age, medical history, previous blood-glucose findings and other factors differ between relatives. A national group average does not establish that each member has the same probability of illness or needs the same screening schedule.
This is the Indian-Canadian relevance of the evidence: South Asian ancestry is recognised in clinical risk assessment, but a family should use that information alongside its own health history. The population label supplies one part of the discussion. It does not replace the rest of the clinical assessment.
Why can different Canadian reports give different percentages?
They may cover different years, populations, age structures and methods. The Public Health Agency of Canada’s report on inequalities among racialized adults, published in 2022, uses pooled 2015–2018 survey data and age-standardised estimates. That is a different basis from the 2023 table.
Age-standardisation adjusts comparisons to a common age distribution. It helps address the fact that diabetes prevalence generally changes with age. An unadjusted group share and an age-standardised estimate should not be treated as alternative counts of exactly the same thing.
Other sources use health-administration records or laboratory measurements. A survey asking about known diabetes cannot identify every person who has not yet been diagnosed. A study measuring blood glucose can detect a different set of cases, while an administrative definition depends on how medical encounters and diagnoses are recorded.
Before deciding that a rate has risen or fallen, compare the source years and definitions. Two percentages from different methods do not establish a trend. The useful task is to find a like-for-like series, with its uncertainty and exclusions, rather than choose whichever number seems most striking.
Can the figures explain why a particular person has diabetes?
No. A descriptive prevalence table does not establish the cause of a particular person’s condition. It does not isolate genetics, income, food access, activity, medication, migration experience or access to diagnosis as the single explanation for a group difference.
The Public Health Agency of Canada’s risk guidance identifies several factors relevant to type 2 diabetes, including age, family history and membership of populations with higher risk. It also distinguishes factors people can influence from those they cannot change. Ancestry should be discussed in that wider setting.
Avoid turning a population result into a claim that Indian food, migration or one cultural practice caused a person’s illness. A table that does not measure those explanations cannot prove them. Diet and activity advice should respond to the individual’s needs and circumstances rather than assumptions about what everyone in a community eats or does.
For someone already diagnosed, the immediate questions concern the type of diabetes, the treatment plan and the monitoring or follow-up required. An ancestry statistic cannot tell them to start, stop or change medication. Nor does a favourable national average remove the need to follow a clinician’s advice.
What does current screening guidance recommend?
Diabetes Canada’s published screening guidance recommends screening for type 2 diabetes using fasting plasma glucose and/or glycated haemoglobin, or A1C, every three years for people aged 40 and older or those at high risk on a validated risk calculator. Earlier or more frequent screening can be appropriate where additional risk factors are present.
Its screening and diagnosis resources are intended to support health professionals. The underlying screening chapter is part of the 2018 clinical practice guidelines and remains available through the organisation’s guidance. A person’s age, history and symptoms need consideration before turning a general interval into an appointment plan.
Bring the relevant family history to the conversation, including which close relatives have type 2 diabetes, any previous high blood-glucose result and a history of diabetes in pregnancy. Ask which screening test is appropriate, what preparation it requires and what happens if the result is outside the expected range.
Screening and diagnosis are different steps. A clinician may need to interpret or confirm a test result rather than make a diagnosis from a single home reading or an online risk score. If symptoms are causing concern, seek a clinical assessment rather than waiting for a routine screening anniversary.
What can CANRISK tell a family?
CANRISK is a questionnaire for identifying people who may be at higher risk of prediabetes or type 2 diabetes. The official questionnaire specifies adults aged 40 to 74 in its original published version. It asks about several factors, including age, body measurements, family history, previous high blood glucose and ancestry.
The tool can help structure a discussion, but it is not a blood test or a diagnosis. Its stated age range matters, particularly when a younger adult is concerned about family history. Do not interpret a questionnaire’s score as proving that a person is free of diabetes or as a reason to avoid a medical appointment.
A 2018 study published by PHAC examined CANRISK’s performance among Canadian South Asian participants below and above 40. Its consideration of age-specific cut-offs is a reminder that a tool’s performance depends on the population and the threshold used. A family should not redesign the scoring system for itself.
The practical use is to take the completed information to a health professional and discuss whether screening is indicated. The distinction between a risk tool and diagnostic testing prevents an apparently precise score from being treated as a personalised clinical conclusion.
What does recent research add to that conversation?
An April 2026 PHAC-journal study of pharmacists’ experiences with CANRISK concerns how the questionnaire and its user guide are implemented. It does not replace the 2023 population prevalence table or establish a new diabetes rate for Indian-Canadians. The researchers also discuss newer work extending the questionnaire’s use among younger and more diverse populations. The original age range should therefore be treated as a version-specific instruction, rather than the final word on every use of CANRISK.
That distinction is useful when research findings reach family messages or social media. A study of a screening tool, a study of healthcare access and a national prevalence estimate can each contribute evidence, but they are not interchangeable. Look for the question the researchers actually asked before deciding what a result permits you to infer.
The next improvement in a family’s understanding may come from a clearer explanation of an existing test or guideline. It need not wait for a new national percentage. Good evidence should make the next clinical conversation more specific, rather than encourage another round of self-diagnosis from a headline.
The study identifies practical obstacles such as limited time, competing priorities and staff or resource pressures. Its sample and recruitment limitations mean the findings cannot establish a national rate of questionnaire use. A tool being available and a family being offered an assessment are different steps.
For a family, the useful question is whether the practice offers an appropriate assessment and how any result will be followed up. Ask which version of the questionnaire is being used and whether it is suitable for the person’s age and circumstances. Bring previous test results and a clear family history, rather than trying to infer a diagnosis from a score alone.
How can advice reflect a family’s language and everyday life?
Use reliable resources that a person can understand and discuss with their care team. Fraser Health’s South Asian Health Institute works on culturally relevant resources and community engagement. Its diabetes information links to Punjabi material as well as English resources.
In a June 2025 research-engagement account, the health authority described a questionnaire shared in English, Hindi and Punjabi to ask community members about their health research priorities. That is a dated example of involving South Asian residents in setting research questions, rather than assuming the institution already knows their concerns.
At an appointment, ask for explanations of food portions, activity and follow-up that work with the person’s usual meals, budget and responsibilities. If language is a barrier, ask the service what interpretation or translated information is available. Another family’s experience can be supportive, but it does not establish the right treatment for someone else.
Related Indian diaspora coverage and the account of an Indian-trained nurse’s registration journey in Canada provide community and healthcare context. Clinical decisions still require the individual’s own history, examination and appropriate tests.
What should a family do next?
Take the relevant family and personal history to a clinician, ask whether screening is appropriate and agree how the results will be explained. Keep the source and year beside any statistic shared with relatives. The 2023 population estimate should remain labelled 2023 when circulated in 2026.
Future survey releases can update the national picture, while clinical guidance may refine screening and care. For the next appointment, the useful outcome is a personal assessment and a clear follow-up plan. The population evidence gives a reason to ask informed questions; it cannot supply that plan on its own.
_Blood_glucose_meter_07.jpg){kind=link}